이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

IIB-IIIB기(N2) 절제 가능한 NSCLC 환자에서 신보강 화학요법과 Durvalumab을 병용한 후 보조 Durvalumab을 추가하는 이점을 평가하기 위한 국제, 다기관, 공개 무작위 3상 시험 (ADOPT-lung)

2026년 11월 11일 업데이트: ETOP IBCSG Partners Foundation

ADOPT-lung is an international, multicentre, open-label randomised phase III trial. Protocol treatment consists of 3-4 cycles of neoadjuvant durvalumab in combination with platinum-based doublet chemotherapy, followed by surgery. Patients with R0 and R1 only resection will be randomised to receive either adjuvant durvalumab for 12 cycles (experimental arm) or observation (control arm). The primary objective of the study is to determine whether additional adjuvant immunotherapy with durvalumab after neoadjuvant chemo-immunotherapy has an effect on disease-free survival (DFS) in patients who do not achieve complete pathological response (pCR) as per local assessment according to the IASLC recommendations.

연구 개요

상태

모병

연구 유형

중재적

등록 (추정된)

290

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

      • Anderlecht, 벨기에
      • Antwerp, 벨기에
        • 모병
        • Antwerp University Hospital
        • 연락하다:
          • Reinier Wener
      • Baden, 스위스
      • Basel, 스위스
      • Bellinzona, 스위스
      • Bern, 스위스
      • Fribourg, 스위스
      • Lausanne, 스위스
      • Sankt Gallen, 스위스
      • Winterthur, 스위스
      • Zurich, 스위스
      • Dublin, 아일랜드
      • Dublin, 아일랜드
        • 모병
        • St James's Hospital
        • 연락하다:
      • Cardiff, 영국
        • 모병
        • Velindre University NHS Trust
        • 연락하다:
          • Paul Shaw
      • Glasgow, 영국
        • 아직 모집하지 않음
        • Beatson West of Scotland Cancer Centre NHS Greater Glasgow and Clyde
        • 연락하다:
          • Nicola Steele
      • London, 영국
      • London, 영국
        • 아직 모집하지 않음
        • Royal Marsden Hospital (Chelsea)
        • 연락하다:
      • London, 영국
        • 아직 모집하지 않음
        • Royal Marsden Hospital (Sutton)
        • 연락하다:
      • Maidstone, 영국
        • 모병
        • Maidstone and Tunbridge Wells NHS Trust
        • 연락하다:
      • Manchester, 영국
        • 모병
        • Wythenshawe Hospital, Manchester University NHS Foundation Trust
        • 연락하다:
      • Alessandria, 이탈리아
        • 아직 모집하지 않음
        • SS Antonio e Biagio e Cesare Arrigo Hospital
        • 연락하다:
      • Padova, 이탈리아
      • Perugia, 이탈리아
      • Rome, 이탈리아
        • 모병
        • Istituto Nazionale Tumori "Regina Elena"
        • 연락하다:
      • Siena, 이탈리아
        • 아직 모집하지 않음
        • AOUS Policlinico Le Scotte
        • 연락하다:
      • Verona, 이탈리아
    • New South Wales
      • Camperdown, New South Wales, 호주
        • 아직 모집하지 않음
        • Chris O'Brien Lifehouse
        • 연락하다:
          • Malinda Itchins
      • Penrith, New South Wales, 호주
        • 모병
        • Nepean Hospital
        • 연락하다:
          • Deme Karikios
      • St Leonards, New South Wales, 호주
        • 모병
        • Royal North Shore Hospital
        • 연락하다:
          • Malinda Itchins
    • Queensland
      • Woolloongabba, Queensland, 호주
        • 아직 모집하지 않음
        • Princess Alexandra Hospital
        • 연락하다:
          • Kenneth O'Bryne
    • South Australia
      • Bedford Park, South Australia, 호주
        • 아직 모집하지 않음
        • Flinders Medical Centre
        • 연락하다:
          • Chris Karapetis
    • Tasmania
      • Hobart, Tasmania, 호주
        • 아직 모집하지 않음
        • Royal Hobart Hospital
        • 연락하다:
          • Rebecca Tay
    • Victoria
      • Box Hill, Victoria, 호주
        • 모병
        • Eastern Health
        • 연락하다:
          • Phillip Parente
      • Melbourne, Victoria, 호주
        • 모병
        • Alfred Hospital
        • 연락하다:
          • Maggie Moore
      • Parkville, Victoria, 호주
        • 모병
        • Peter MacCallum Cancer Centre
        • 연락하다:
          • Benjamin Solomon
    • Western Australia
      • Nedlands, Western Australia, 호주
        • 아직 모집하지 않음
        • Sir Charles Gairdner Hospital
        • 연락하다:
          • Samantha Bowyer

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria for enrolment:

  • Histologically confirmed NSCLC.
  • Stage IIB-IIIB (T1-4 N0-2) according to 8th edition of the TNM staging system of lung cancer.

Stage III assessment should include samples of lymph nodes at levels 4, bilaterally, and level 7 to rule out stage IIIB N3 disease.

T4 tumours will only be eligible if they are defined as T4 based only on their size (>7cm); any other reason will be considered ineligible.

  • Known PD-L1 status, as tested locally using a validated assay. To ensure comparability of results, it is strongly encouraged that PD-L1 testing is done with the Ventana PD-L1 (SP263) assay.
  • Absence of EGFR mutation or ALK translocation, as tested locally.
  • Primary tumour resectable and functionally operable as assessed per local multidisciplinary tumour board (cardiac evaluation, pulmonary function and diffusion capacity, comorbidity).
  • Adequate haematological function:

Haemoglobin ≥90 g/L, Absolute neutrophil count (ANC) ≥1.0× 109/L, Platelet count ≥75× 109/L.

- Adequate renal function: Measured creatinine clearance (CL) >40 mL/min or calculated CL >40 mL/min calculated by the Cockcroft-Gault.

- Adequate liver function: ALT and AST ≤2.5× institutional ULN, Total serum bilirubin ≤1.5× institutional ULN (patients with Gilbert's syndrome may be allowed to be enrolled after consultation with the Medical Affairs Team at the ETOP IBCSG Partners Foundation.

  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
  • Age ≥18 at the time of enrolment.
  • Body weight >30 kg.
  • Life expectancy of at least 12 weeks.
  • Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative urinary or serum pregnancy test at screening before enrolment. Pregnancy test must be repeated within 3 days before the first dose of protocol treatment.
  • Written IC for study participation must be signed and dated by the patient and the investigator prior to any study-related intervention.

Eligibility Criteria for randomisation:

  • Surgical resection must have been completed. Note: Participants who have had only had segmentectomy or wedge resections are not eligible for randomisation.
  • Patients must have complete resection: R0 or R1 resection.
  • Patients must be fit to receive adjuvant treatment with durvalumab.
  • Patients must have no evidence of metastatic disease as assessed by CT scan.
  • Documentation of pathological response as per local review must be available.

Exclusion Criteria for enrolment:

  • T4 with invasion of heart, great vessels, carina, trachea, oesophagus, or spine.
  • Any previous or concurrent treatments for NSCLC.
  • Any previous immunotherapy.
  • Major surgical procedure (as per investigators assessment) within 28 days before enrolment.
  • History of allogenic organ transplantation.
  • Active or prior documented autoimmune disease or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.]). The following are exceptions to this criterion:

Patients with vitiligo or alopecia. Patients with type I diabetes. Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement.

Any chronic skin condition that does not require systemic therapy. Patients without active disease in the last 5 years may be included but only after consultation with the Medical Affairs Team at the ETOP IBCSG Partners Foundation.

Patients with celiac disease controlled by diet alone.

  • Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease (ILD), or serious chronic gastrointestinal conditions associated with diarrhoea.
  • Psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.
  • History of another primary malignancy except for:

Malignancy treated with curative-intent and with no known active disease 5 years before the first dose of durvalumab and of low potential risk for recurrence.

Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.

Adequately treated carcinoma in situ without evidence of disease.

  • History of leptomeningeal carcinomatosis.
  • History of active primary immunodeficiency.
  • Active hepatitis infection, positive hepatitis C virus (HCV) antibody, hepatitis B virus (HBV) surface antigen (HbsAg) or HBV core antibody (anti-HBc).

Participants with a past or resolved HBV infection (defined as the presence of anti-HBc and absence of HbsAg) are eligible.

Participants positive for HCV antibody are only eligible if polymerase chain reaction is negative for HCV RNA.

  • Known HIV infection that is not well-controlled. All of the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA load for 3 months, CD4+ count of 500 cell per mm3, no history of AIDS-defining opportunistic infection within the past 12 months, and stable for at least 3 months on the same anti-HIV medication.
  • Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:

Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection).

Systemic corticosteroids at physiologic doses not exceeding 10 mg/day of prednisone or its equivalent.

Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).

- Receipt of live attenuated vaccine within 30 days prior to the first dose of durvalumab.

Note: Patients in the ADOPT-lung trial, should not receive live vaccine whilst receiving durvalumab and for up to 30 days after the last dose.

Concurrent enrolment in another interventional clinical trial.

  • Known allergy or suspected hypersensitivity to durvalumab or its excipients.
  • Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
  • Female patients who are pregnant or in the period of lactation.
  • Female patients of childbearing potential and sexually active men who are not willing to use a highly effective contraceptive method during the trial until at least 90 days after the last dose of protocol treatment.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Durvalumab

Protocol treatment in the adjuvant phase consists of adjuvant durvalumab

Durvalumab is given at a fixed dose of 1500 mg i.v. every 4 weeks (±1 week) until relapse or unacceptable toxicity, for a maximum of 12 cycles after surgery.

간섭 없음: Observation

Observation only

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Disease-free survival (DFS)
기간: From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)

Assessed in the adjuvant treatment phase.

DFS is defined as the time from the date of randomisation until disease recurrence (including loco-regional recurrence, a distant (metastatic) recurrence or a second primary) or death from any cause. Censoring (for patients without recurrence/death) will occur at the date of last tumour assessment. Patients without a post-randomisation tumour assessment will be censored at the date of randomisation (plus 1 day). DFS will be assessed in patients without pCR (primary endpoint), as well as in patients with pCR (secondary endpoint) and in patients with/without ctDNA clearance (secondary endpoints).

From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)

2차 결과 측정

결과 측정
측정값 설명
기간
DFS in patients with pCR
기간: From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)

Assessed in the adjuvant treatment phase (after randomisation).

DFS is defined as the time from the date of randomisation until disease recurrence (including loco-regional recurrence, a distant (metastatic) recurrence or a second primary) or death from any cause. Censoring (for patients without recurrence/death) will occur at the date of last tumour assessment. Patients without a post-randomisation tumour assessment will be censored at the date of randomisation (plus 1 day). DFS will be assessed in patients without pCR (primary endpoint), as well as in patients with pCR (secondary endpoint) and in patients with/without ctDNA clearance (secondary endpoints).

From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
Overall survival (OS) in patients with/without pCR
기간: From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)

Assessed in the adjuvant treatment phase (after randomisation).

OS is defined as the time from the date of randomisation until death from any cause. Censoring (for patients who are not reported as having died) will occur at the date when they were last known to be alive. Patients without post-randomisation information will be censored at the date of randomisation (plus 1 day). OS will be assessed in patients with/without pCR.

From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
DFS in patients with/without ctDNA clearance
기간: From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)

Assessed in the adjuvant treatment phase (after randomisation).

From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
Time to recurrence (TTR) in patients with/without pCR
기간: From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)

Assessed in the adjuvant treatment phase (after randomisation).

TTR is defined as the time from the date of randomisation until disease recurrence. Censoring (for patients without recurrence) will occur at the date of the last tumour assessment. Patients without a post-randomisation tumour assessment will be censored at the date of randomisation (plus 1 day). TTR will be assessed in patients with/without pCR.

From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
Time to treatment discontinuation (TTD) in patients with/without pCR
기간: From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)

Assessed in the adjuvant treatment phase (after randomisation).

From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)
Toxicity according to CTCAE v5.0
기간: From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)

Assessed in the adjuvant treatment phase (after randomisation).

All safety parameters will be summarised in tables to evaluate the toxicity/safety profile of the protocol treatment based on:

  • Adverse events according to CTCAE v5.0 (any-cause as well as treatment-related) including adverse events leading to dose interruptions, withdrawal of protocol treatment, and death.
  • Severe, serious, and selected adverse events.
  • Deaths.
  • Laboratory parameters and abnormalities, and vital signs.
From the date of randomisation until last patient last visit (approximately 60 months after randomisation of the first patient)

기타 결과 측정

결과 측정
측정값 설명
기간
Correlation between ctDNA clearance and DFS
기간: From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)

Exploratory endpoint

From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
Correlation between ctDNA clearance and OS
기간: From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)

Exploratory endpoint

From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
Correlation between ctDNA clearance and initial PD-L1 assessment
기간: From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)

Exploratory endpoint

From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
Outcome (event-free survival)
기간: From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)

Outcome (EFS) in patients with patients with either

  • ctDNA clearance after neoadjuvant treatment but not achieving pCR
  • no ctDNA clearance after neoadjuvant treatment but achieving pCR
From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
Correlation of Outcome Disease-free survival (DFS)
기간: From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)

Correlation of Outcome (DFS) in patients with longitudinal ctDNA assessment

From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
Correlation of Outcome Overall survival (OS)
기간: From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)

Correlation of Outcome (OS) in patients with longitudinal ctDNA assessment

From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)
pCRDescription of patients entering each phase (e.g., % surgery, % randomised)
기간: From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)

pCRDescription of patients entering each phase (e.g., % surgery, % randomised)

From the date of screening until last patient last visit (approximately 60 months after randomisation of the first patient)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

협력자

수사관

  • 연구 의자: Solange Peters, MD-PhD, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland
  • 연구 의자: Sabine Schmid, MD, Inselspital, Universitätsspital Bern, 3010 Bern, Switzerland
  • 연구 의자: Paul Van Schil, MD-PhD, Antwerp University Hospital, Antwerp, Belgium,
  • 연구 의자: Stephen Finn, MD-PhD, St. James's Hospital, Dublin 8, Ireland

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 1월 15일

기본 완료 (추정된)

2029년 10월 1일

연구 완료 (추정된)

2030년 3월 1일

연구 등록 날짜

최초 제출

2024년 2월 21일

QC 기준을 충족하는 최초 제출

2024년 2월 21일

처음 게시됨 (실제)

2024년 2월 28일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 16일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 11일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다